Assessment for Long-Term Cardiovascular Impairment Associated With Trastuzumab Cardiotoxicity in HER2-Positive Breast Cancer Survivors

Memorial Sloan Kettering Cancer Center (MSK) logo

Memorial Sloan Kettering Cancer Center (MSK)

Status

Completed

Conditions

Trastuzumab Cardiotoxicity
HER2-Positive Breast Cancer Survivors

Treatments

Device: Cardiopulmonary exercise testing and post-CPET cardiac function
Device: 2D Echocardiogram

Study type

Observational

Funder types

Other

Identifiers

NCT02615054
15-258

Details and patient eligibility

About

This is for participants with a history of HER2-positive breast cancer and were treated with chemotherapy that increases the risk of abnormal heart function. Strain (a marker of heart function) is a new method of monitoring heart function in cancer patients and is measured with an ultrasound. Exercise testing is another method that can be used to monitor for abnormal heart function in cancer patients. The purpose of this study is to see if strain and exercise testing can be used to detect for late signs of heart damage from chemotherapy.

Enrollment

58 patients

Sex

Female

Ages

18+ years old

Volunteers

Accepts Healthy Volunteers

Inclusion criteria

All patients:

  • Aged ≥ 18 years
  • Female
  • MSK histologically confirmed primary invasive breast carcinoma
  • Pathologically confirmed HER2-positive breast cancer
  • Treated with adjuvant trastuzumab (either alone or in combination with other anti-HER2 agents)
  • ≥ 2 years since completion of targeted chemotherapy without evidence of disease
  • Willing and able to comply with the requirements of the protocol

Patients in the cardiotoxicity (TOX) group must meet the following criteria:

  • Development of treatment associated cardiotoxicity during trastuzumab therapy, defined as an absolute decrease from baseline in LVEF by ≥ 10%, to an LVEF of below 55%.
  • No clinical signs or symptoms of heart failure (NYHA class III or IV) at the time of cardiotoxicity.

Note: NYHA Class III symptoms include marked limitation of physical activity. Less than ordinary activity causes fatigue, palpitation, dyspnea, or anginal pain. NYHA Class IV symptoms include inability to carry on any physical activity without discomfort. Symptoms of heart failure or anginal syndrome may be present at rest, and if any physical activity is undertaken, discomfort is increased.

Patients in the no cardiotoxicity (NO-TOX) group must meet the following criteria:

  • Maximum absolute decrease in LVEF ≤ 5% from baseline during trastuzumab therapy.
  • Echocardiogram with LVEF assessment performed at baseline (prior to initiation of trastuzumab therapy) and at least two timepoints during trastuzumab therapy.
  • LVEF ≥ 55% on each echocardiogram assessment during trastuzumab therapy.
  • No clinical signs or symptoms of heart failure (NYHA class III or IV) during trastuzumab treatment.

Note: NYHA Class III symptoms include marked limitation of physical activity. Less than ordinary activity causes fatigue, palpitation, dyspnea, or anginal pain. NYHA Class IV symptoms include inability to carry on any physical activity without discomfort. Symptoms of heart failure or anginal syndrome may be present at rest, and if any physical activity is undertaken, discomfort is increased.

Participants in the healthy control group must meet the following criteria:

  • Aged ≥ 40 years
  • Female
  • No history of cancer with the exception of localized basal and/or squamous cell carcinoma of the skin
  • No prior history of known cardiac disease (e.g. ischemic heart disease, heart failure, cardiomyopathy, or valvular heart disease [moderate to severe], or significant arrhythmias).
  • Willing and able to comply with the requirements of the protocol

Exclusion criteria

  • Inability to provide informed consent
  • Presence of metastatic disease
  • Treatment with additional cardiotoxic therapy for a secondary malignant neoplasm, or treatment with additional cardiotoxic therapy for breast cancer recurrence since primary breast cancer diagnosis [Note: Patients who are diagnosed with a second primary malignancy are not excluded from participation in the study, unless they meet this exclusion criterion.]
  • Subjects must not have any of the following absolute contraindications to cardiopulmonary exercise testing : (a) acute myocardial infarction (within 3-5 days of any planned study procedures), (b) unstable angina, (c) uncontrolled arrhythmias causing symptoms or hemodynamic compromise, (d) symptomatic severe aortic stenosis, (e) recurrent syncope, (f) active endocarditis, (g) acute myocarditis or pericarditis, (h) uncontrolled heart failure, (i) acute pulmonary embolus or pulmonary infarction, (within 3 months of any planned study procedures), (j) thrombosis of lower extremities, (k) suspected dissecting aneurysm, (l) uncontrolled asthma, (m) pulmonary edema (within 3 months of planned study procedures), (n) room air desaturation at rest ≤85%, (o) respiratory failure, (p) acute noncardiopulmonary disorder that may affect exercise performance or be aggravated by exercise (i.e., infection, renal failure, thyrotoxicosis), or (q) mental impairment leading to inability to cooperate.

Trial design

58 participants in 3 patient groups

treated with trastuzmab no cardiac effects
Treatment:
Device: 2D Echocardiogram
Device: Cardiopulmonary exercise testing and post-CPET cardiac function
treated with trastuzmab with cardiac effects
Treatment:
Device: 2D Echocardiogram
Device: Cardiopulmonary exercise testing and post-CPET cardiac function
healthy volunteers no cancer treatment
Treatment:
Device: 2D Echocardiogram
Device: Cardiopulmonary exercise testing and post-CPET cardiac function

Trial contacts and locations

1

Loading...

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems